Cargando…

The Application Value of the Central Lymph Node Metastasis Risk Assessment Model in Papillary Thyroid Microcarcinoma of Stage cN0: A Study of 828 Patients

BACKGROUND: The aim of this study is to build a risk assessment system for central lymph node metastasis (CLNM) in papillary thyroid microcarcinoma (PTMC) of stage cN0 and to explore its application value in clinical practice. METHODS: A total of 500 patients with PTMC who underwent thyroid operatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jinqiu, Sheng, Xianneng, Dai, Yongping, Zhang, Jiabo, Song, Lihua, Guo, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960455/
https://www.ncbi.nlm.nih.gov/pubmed/35360071
http://dx.doi.org/10.3389/fendo.2022.843573
_version_ 1784677387407982592
author Wang, Jinqiu
Sheng, Xianneng
Dai, Yongping
Zhang, Jiabo
Song, Lihua
Guo, Yu
author_facet Wang, Jinqiu
Sheng, Xianneng
Dai, Yongping
Zhang, Jiabo
Song, Lihua
Guo, Yu
author_sort Wang, Jinqiu
collection PubMed
description BACKGROUND: The aim of this study is to build a risk assessment system for central lymph node metastasis (CLNM) in papillary thyroid microcarcinoma (PTMC) of stage cN0 and to explore its application value in clinical practice. METHODS: A total of 500 patients with PTMC who underwent thyroid operation from 2013 to 2015 in Ningbo First Hospital were selected as the model group. Independent risk factors related to CLNM in PTMC were analyzed and determined, and a risk assessment system for CLNM was preliminarily established. Furthermore, the clinicopathological data from 328 PTMC patients with the same conditions as the model group from 2016 to 2017 were further collected as the validation group to verify the diagnostic value of the risk assessment system. RESULTS: The risk assessment system was based on the score rating (score ≤ 5 was classified as low risk, 6–8 was classified as medium risk, and ≥9 was classified as high-risk). The area under the receiver operating characteristic curve (ROC) was 0.687 (95% CI: 0.635–0.783). According to the risk assessment system, 328 PTMC patients in the validation group were scored. Among the low-risk group, the moderate-risk group, and the high-group, 96.8%, 58.1%, and 43.2% were the CLNM (-) patients, and 3.1%, 41.9%, and 65.8% were CLNM (+) patients, respectively. The area under ROC was 0.837 (95% CI: 0.778–0.869). CONCLUSIONS: The risk assessment system in this study is of diagnostic value and can provide a theoretical foundation for intraoperative decision-making of prophylactic central neck dissection (pCND).
format Online
Article
Text
id pubmed-8960455
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89604552022-03-30 The Application Value of the Central Lymph Node Metastasis Risk Assessment Model in Papillary Thyroid Microcarcinoma of Stage cN0: A Study of 828 Patients Wang, Jinqiu Sheng, Xianneng Dai, Yongping Zhang, Jiabo Song, Lihua Guo, Yu Front Endocrinol (Lausanne) Endocrinology BACKGROUND: The aim of this study is to build a risk assessment system for central lymph node metastasis (CLNM) in papillary thyroid microcarcinoma (PTMC) of stage cN0 and to explore its application value in clinical practice. METHODS: A total of 500 patients with PTMC who underwent thyroid operation from 2013 to 2015 in Ningbo First Hospital were selected as the model group. Independent risk factors related to CLNM in PTMC were analyzed and determined, and a risk assessment system for CLNM was preliminarily established. Furthermore, the clinicopathological data from 328 PTMC patients with the same conditions as the model group from 2016 to 2017 were further collected as the validation group to verify the diagnostic value of the risk assessment system. RESULTS: The risk assessment system was based on the score rating (score ≤ 5 was classified as low risk, 6–8 was classified as medium risk, and ≥9 was classified as high-risk). The area under the receiver operating characteristic curve (ROC) was 0.687 (95% CI: 0.635–0.783). According to the risk assessment system, 328 PTMC patients in the validation group were scored. Among the low-risk group, the moderate-risk group, and the high-group, 96.8%, 58.1%, and 43.2% were the CLNM (-) patients, and 3.1%, 41.9%, and 65.8% were CLNM (+) patients, respectively. The area under ROC was 0.837 (95% CI: 0.778–0.869). CONCLUSIONS: The risk assessment system in this study is of diagnostic value and can provide a theoretical foundation for intraoperative decision-making of prophylactic central neck dissection (pCND). Frontiers Media S.A. 2022-03-10 /pmc/articles/PMC8960455/ /pubmed/35360071 http://dx.doi.org/10.3389/fendo.2022.843573 Text en Copyright © 2022 Wang, Sheng, Dai, Zhang, Song and Guo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Wang, Jinqiu
Sheng, Xianneng
Dai, Yongping
Zhang, Jiabo
Song, Lihua
Guo, Yu
The Application Value of the Central Lymph Node Metastasis Risk Assessment Model in Papillary Thyroid Microcarcinoma of Stage cN0: A Study of 828 Patients
title The Application Value of the Central Lymph Node Metastasis Risk Assessment Model in Papillary Thyroid Microcarcinoma of Stage cN0: A Study of 828 Patients
title_full The Application Value of the Central Lymph Node Metastasis Risk Assessment Model in Papillary Thyroid Microcarcinoma of Stage cN0: A Study of 828 Patients
title_fullStr The Application Value of the Central Lymph Node Metastasis Risk Assessment Model in Papillary Thyroid Microcarcinoma of Stage cN0: A Study of 828 Patients
title_full_unstemmed The Application Value of the Central Lymph Node Metastasis Risk Assessment Model in Papillary Thyroid Microcarcinoma of Stage cN0: A Study of 828 Patients
title_short The Application Value of the Central Lymph Node Metastasis Risk Assessment Model in Papillary Thyroid Microcarcinoma of Stage cN0: A Study of 828 Patients
title_sort application value of the central lymph node metastasis risk assessment model in papillary thyroid microcarcinoma of stage cn0: a study of 828 patients
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960455/
https://www.ncbi.nlm.nih.gov/pubmed/35360071
http://dx.doi.org/10.3389/fendo.2022.843573
work_keys_str_mv AT wangjinqiu theapplicationvalueofthecentrallymphnodemetastasisriskassessmentmodelinpapillarythyroidmicrocarcinomaofstagecn0astudyof828patients
AT shengxianneng theapplicationvalueofthecentrallymphnodemetastasisriskassessmentmodelinpapillarythyroidmicrocarcinomaofstagecn0astudyof828patients
AT daiyongping theapplicationvalueofthecentrallymphnodemetastasisriskassessmentmodelinpapillarythyroidmicrocarcinomaofstagecn0astudyof828patients
AT zhangjiabo theapplicationvalueofthecentrallymphnodemetastasisriskassessmentmodelinpapillarythyroidmicrocarcinomaofstagecn0astudyof828patients
AT songlihua theapplicationvalueofthecentrallymphnodemetastasisriskassessmentmodelinpapillarythyroidmicrocarcinomaofstagecn0astudyof828patients
AT guoyu theapplicationvalueofthecentrallymphnodemetastasisriskassessmentmodelinpapillarythyroidmicrocarcinomaofstagecn0astudyof828patients
AT wangjinqiu applicationvalueofthecentrallymphnodemetastasisriskassessmentmodelinpapillarythyroidmicrocarcinomaofstagecn0astudyof828patients
AT shengxianneng applicationvalueofthecentrallymphnodemetastasisriskassessmentmodelinpapillarythyroidmicrocarcinomaofstagecn0astudyof828patients
AT daiyongping applicationvalueofthecentrallymphnodemetastasisriskassessmentmodelinpapillarythyroidmicrocarcinomaofstagecn0astudyof828patients
AT zhangjiabo applicationvalueofthecentrallymphnodemetastasisriskassessmentmodelinpapillarythyroidmicrocarcinomaofstagecn0astudyof828patients
AT songlihua applicationvalueofthecentrallymphnodemetastasisriskassessmentmodelinpapillarythyroidmicrocarcinomaofstagecn0astudyof828patients
AT guoyu applicationvalueofthecentrallymphnodemetastasisriskassessmentmodelinpapillarythyroidmicrocarcinomaofstagecn0astudyof828patients